Published in Invest Ophthalmol Vis Sci on August 01, 1996
Mechanisms of age-related macular degeneration. Neuron (2012) 2.62
Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Mol Aspects Med (2012) 2.37
Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol (1998) 2.33
Bimonthly injections of ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2014) 2.04
Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res (2005) 1.84
Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res (2010) 1.79
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.76
A comprehensive review of retinal gene therapy. Mol Ther (2013) 1.70
Therapeutic targets in age-related macular disease. J Clin Invest (2010) 1.68
Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2003) 1.64
Vascular endothelial growth factor and ocular neovascularization. Am J Pathol (1997) 1.56
The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest (2005) 1.56
Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol (2005) 1.54
Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol (2001) 1.53
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov (2012) 1.52
Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol (2004) 1.52
Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med (2010) 1.45
Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol (2006) 1.39
Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 1.34
Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Br J Ophthalmol (1997) 1.29
Age-related macular degeneration: genetic and environmental factors of disease. Mol Interv (2010) 1.24
Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. Am J Pathol (2007) 1.23
Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol (2011) 1.20
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2008) 1.17
Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2010) 1.17
Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv Cancer Res (2012) 1.17
Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2006) 1.16
Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflamm (2010) 1.11
Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat. Br J Ophthalmol (1998) 1.11
Ocular neovascularization: clarifying complex interactions. Am J Pathol (1998) 1.11
Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis (2008) 1.08
A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. Invest Ophthalmol Vis Sci (2010) 1.06
Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol (2008) 1.05
Biology and therapy of inherited retinal degenerative disease: insights from mouse models. Dis Model Mech (2015) 1.05
Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther (2010) 1.02
Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol (2006) 1.02
Suppression and regression of choroidal neovascularization in mice by a novel CCR2 antagonist, INCB3344. PLoS One (2011) 1.01
Angiogenesis in eye disease: immunity gained or immunity lost? Semin Immunopathol (2008) 1.00
Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol (2013) 0.99
One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups. Jpn J Ophthalmol (2009) 0.99
Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response. Arch Ophthalmol (2009) 0.98
Altered gene expression in dry age-related macular degeneration suggests early loss of choroidal endothelial cells. Mol Vis (2013) 0.98
The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol (2007) 0.97
Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol (2012) 0.97
Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J Ophthalmol (2011) 0.97
CNTF mediates neurotrophic factor secretion and fluid absorption in human retinal pigment epithelium. PLoS One (2011) 0.97
Cigarette smoke-related hydroquinone dysregulates MCP-1, VEGF and PEDF expression in retinal pigment epithelium in vitro and in vivo. PLoS One (2011) 0.96
Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2016) 0.96
Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol (2007) 0.96
Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration. Int Ophthalmol (2009) 0.95
Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes. Expert Opin Drug Deliv (2010) 0.94
Alternative therapies in exudative age related macular degeneration. Br J Ophthalmol (1998) 0.93
Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol (2010) 0.93
The choroid as a sclera growth regulator. Exp Eye Res (2013) 0.92
Total chemical synthesis of biologically active vascular endothelial growth factor. Angew Chem Int Ed Engl (2011) 0.91
Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis. Clin Interv Aging (2014) 0.91
Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis (2008) 0.90
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians. J Ophthalmol (2011) 0.90
Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. Trans Am Ophthalmol Soc (2008) 0.90
Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol (2001) 0.89
Genetic loci that control the size of laser-induced choroidal neovascularization. FASEB J (2009) 0.89
Age-related macular degeneration: a target for nanotechnology derived medicines. Int J Nanomedicine (2007) 0.89
Ranibizumab in neovascular age-related macular degeneration. Clin Interv Aging (2006) 0.89
Thrombin-induced VEGF expression in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci (2007) 0.89
Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration. J Ophthalmic Vis Res (2008) 0.89
Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine (2006) 0.88
Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. Am J Ophthalmol (2007) 0.88
Vascular endothelial growth factor A polymorphisms and age-related macular degeneration: a systematic review and meta-analysis. Mol Vis (2013) 0.88
[Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells]. Ophthalmologe (2007) 0.88
Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo. Invest Ophthalmol Vis Sci (2014) 0.87
Attenuation of choroidal neovascularization by β(2)-adrenoreceptor antagonism. JAMA Ophthalmol (2013) 0.87
Intravitreal ranibizumab in choroidal neovascularisation due to multifocal choroiditis and panuveitis syndrome. BMJ Case Rep (2013) 0.86
Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol (2009) 0.86
Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. Br J Ophthalmol (2006) 0.86
Transforming growth factor-beta inhibition reduces progression of early choroidal neovascularization lesions in rats: P17 and P144 peptides. PLoS One (2013) 0.85
Current status of anti-vascular endothelial growth factor therapy in Europe. Jpn J Ophthalmol (2008) 0.85
VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration. Jpn J Ophthalmol (2011) 0.85
Aflibercept for the treatment of age-related macular degeneration. Ophthalmol Ther (2013) 0.85
Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration. Clin Ophthalmol (2008) 0.85
Effect of brimonidine on retinal and choroidal neovascularization in a mouse model of retinopathy of prematurity and laser-treated rats. Invest Ophthalmol Vis Sci (2011) 0.85
Serum VEGF and CFH in exudative age-related macular degeneration. Curr Eye Res (2010) 0.84
Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6. Invest Ophthalmol Vis Sci (2004) 0.84
Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor. Graefes Arch Clin Exp Ophthalmol (2003) 0.84
Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol (2009) 0.83
Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection. Jpn J Ophthalmol (2015) 0.82
Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study [ISRCTN74123635]. BMC Ophthalmol (2005) 0.82
Intravitreal bevacizumab for choroidal neovascularization secondary to non-age-related macular degeneration. J Ophthalmic Vis Res (2010) 0.82
Surgical induction of choroidal neovascularization in a porcine model. Graefes Arch Clin Exp Ophthalmol (2007) 0.81
PPAR-alpha Ligands as Potential Therapeutic Agents for Wet Age-Related Macular Degeneration. PPAR Res (2008) 0.80
Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2010) 0.80
Hypoxia-induced expression of VEGF splice variants and protein in four retinal cell types. Exp Eye Res (2013) 0.80
Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration. Core Evid (2008) 0.80
VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells. Br J Ophthalmol (2006) 0.80
Human RPE cell apoptosis induced by activated monocytes is mediated by caspase-3 activation. Trans Am Ophthalmol Soc (2003) 0.80
Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab. J Ophthalmol (2013) 0.80
Vascular endothelial growth factors and their inhibitors in ocular neovascular disorders. J Ophthalmic Vis Res (2009) 0.80
Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration. Drug Saf (2015) 0.80
Modulation of choroidal neovascularization by subretinal injection of retinal pigment epithelium and polystyrene microbeads. Mol Vis (2009) 0.79
Gene Transfer of Prolyl Hydroxylase Domain 2 Inhibits Hypoxia-inducible Angiogenesis in a Model of Choroidal Neovascularization. Sci Rep (2017) 0.78
Polymorphisms in the VEGF-A in polypoidal choroidal vasculopathy in a Korean population. Jpn J Ophthalmol (2012) 0.78
Transplantation of fetal retinal pigment epithelium in age-related macular degeneration with subfoveal neovascularization. Graefes Arch Clin Exp Ophthalmol (1994) 2.15
Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci (2001) 1.57
Cut and paste: a no suture, small incision approach to pterygium surgery. Br J Ophthalmol (2004) 1.50
Identification of BK virus in a patient with acquired immune deficiency syndrome and bilateral atypical retinitis. Ophthalmology (1999) 1.44
Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci (1998) 1.29
Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res (2000) 1.15
Localization of adenosine receptor messenger RNAs in the rat eye. Exp Eye Res (1997) 1.13
BK virus as the cause of meningoencephalitis, retinitis and nephritis in a patient with AIDS. AIDS (1999) 1.12
Giant cell angiofibroma. A distinctive orbital tumor in adults. Am J Surg Pathol (1995) 1.11
Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res (1996) 1.10
Transplantation of RPE in age-related macular degeneration: observations in disciform lesions and dry RPE atrophy. Graefes Arch Clin Exp Ophthalmol (1997) 1.10
Risk of acute suprachoroidal hemorrhage with phacoemulsification. J Cataract Refract Surg (1998) 1.03
Matrix metalloproteinase (MMP) expression in experimental choroidal neovascularization. Curr Eye Res (2000) 0.98
New blindness in diabetes reduced by more than one-third in Stockholm County. Diabet Med (1997) 0.98
Photoreceptor decay over time and apoptosis in experimental retinal detachment. Graefes Arch Clin Exp Ophthalmol (1997) 0.96
Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci (2001) 0.95
Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes. Graefes Arch Clin Exp Ophthalmol (1994) 0.94
Epiphora as a side effect of topical mitomycin C. Br J Ophthalmol (2004) 0.92
Intravitreal chemotherapy for recurrent retinoblastoma in an only eye. Br J Ophthalmol (1995) 0.92
Healon Yellow as a surgical tool in maneuvering intraocular tissues. Ophthalmic Surg (1992) 0.91
Patch transplants of human fetal retinal pigment epithelium in rabbit and monkey retina. Invest Ophthalmol Vis Sci (1995) 0.90
Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: a one year follow-up study. Eye (Lond) (2000) 0.90
The Zimmerman-McLean-Foster hypothesis: 25 years later. Br J Ophthalmol (2004) 0.87
Time trends in the incidence of conjunctival melanoma in Sweden. Br J Ophthalmol (2009) 0.85
The EORTC ophthalmic oncology quality of life questionnaire module (EORTC QLQ-OPT30). Development and pre-testing (Phase I-III). Eye (Lond) (2004) 0.85
Blue light induced apoptosis in rat retina. Eye (Lond) (1999) 0.84
Retinal detachment and degeneration in response to subretinal perfluorodecalin in rabbit eyes. Graefes Arch Clin Exp Ophthalmol (1993) 0.83
Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study. Br J Ophthalmol (2001) 0.82
Ocular perforation during retrobulbar and peribulbar injections. Ophthalmic Surg Lasers (1996) 0.82
Limbal sub-Tenon's administration of retrobulbar anesthesia using a blunt irrigating cannula. Ophthalmic Surg Lasers (1996) 0.82
AgNOR counts in conjunctival malignant melanoma lack prognostic value. Br J Ophthalmol (1992) 0.82
Direct puncture and sclerotherapy with sotradecol ((r)) . Orbital lymphatic malformations. Interv Neuroradiol (2001) 0.82
Transpupillary thermotherapy of occult CNV with no or minimally classic CNV in age-related macular degeneration. Semin Ophthalmol (2001) 0.81
Clinical possibilities in retinal pigment epithelial transplantations. Acta Ophthalmol Scand (1997) 0.81
Lipofuscin accumulation in iris pigment epithelial cells exposed to photoreceptor outer segments. Exp Eye Res (1999) 0.81
Cyclosporine treatment of RPE allografts in the rabbit subretinal space. Acta Ophthalmol Scand (2000) 0.80
Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis. Thromb Haemost (2001) 0.80
A prospective randomised study on low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration. Br J Ophthalmol (2008) 0.79
Long-term outcome of RPE allografts to the subretinal space of rabbits. Acta Ophthalmol Scand (1999) 0.79
Cellular migration into neural retina following implantation of melanin granules in the subretinal space. Graefes Arch Clin Exp Ophthalmol (2000) 0.79
Diagnostic incisional biopsies in clinically indeterminate choroidal tumours. Eye (Lond) (2012) 0.79
Risk factors for endophthalmitis following cataract surgery: a retrospective case-control study. J Hosp Infect (2005) 0.79
The Swedish national survey of surgical excision for submacular choroidal neovascularization (CNV). Acta Ophthalmol Scand (2001) 0.78
Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis. Blood (1999) 0.78
Scleral reinforcement by a teflon graft and a tissue adhesive. Acta Ophthalmol (Copenh) (1988) 0.77
Experimental transplantation of autologous iris pigment epithelial cells to the subretinal space. Acta Ophthalmol Scand (2001) 0.76
Fine-needle aspiration biopsy in lacrimal gland pleomorphic adenoma. Eye (Lond) (2009) 0.75
[Radiotherapy of malignant melanoma of the choroid with ruthenium-106 applicator gives good results]. Lakartidningen (1987) 0.75
[Malignant melanoma of the uvea--a review]. Lakartidningen (1987) 0.75
Sealing of retinal breaks with metal tacks. Evaluation of a new procedure in retinal re-attachment surgery. Acta Ophthalmol (Copenh) (1986) 0.75
Proliferating cell nuclear antigen colocalization with corneal epithelial stem cells and involvement in physiological cell turnover. Acta Ophthalmol Scand (1995) 0.75
Photographic detection of retinopathy in insulin-treated diabetes. A population study in the city of Tartu, Estonia. Acta Ophthalmol Scand (1997) 0.75
Improvement of the recurrence-free interval using biological adjuvant therapy in uveal melanoma. Anticancer Res (2000) 0.75
Early detection of diabetic retinopathy by a mobile retinal photography service working in partnership with primary health care teams. Diabet Med (1998) 0.75